Inclusion Criteria:

          -  Disease-related criteria for Part 1 and Part 2: 1) Histologically or cytologically
             documented non-small cell lung cancer (NSCLC) - adenocarcinoma; 2) Stage III b or IV
             disease; 3) Tested for presence of echinoderm microtubule-associated protein-like 4
             anaplastic lymphoma kinase (EML4-ALK) rearrangement; 4) Received at least 2 prior
             lines of Food and Drug Administration (FDA)-approved systemic therapy, of which one
             therapy has to be a platinum-containing regimen OR failed or completed a first-line
             platinum-containing regimen and refused a second-line regimen despite being informed
             about the different therapeutic options and their specific clinical benefit by the
             investigator; the content of this informed consent discussion including the
             therapeutic options reviewed by the investigator needs to be documented and the
             subject needs to sign a specific consent form; Disease-related criteria for Cohort 2B
             only: 1) Mesothelin protein overexpression, defined by immunohistochemistry (IHC) as
             detection of the protein by greater than or equal (>=) 50 percent (%) of tumor cells
             on archived tumor material; 2) Primary tumor or metastatic lesion(s) amenable to tumor
             core biopsies

          -  At least 1 measurable tumor lesion per RECIST v1.1 (exception: subjects in Part 1 are
             not required to present with measurable disease)

          -  Eastern Cooperative Oncology Group (ECOG) Performance status score of 0 to 1

          -  At least 28 days since the last chemotherapy or immunotherapy prior to the first dose;
             at least 14 days since the last radiation prior to the first dose (exception:
             palliative radiotherapy for pain can be used greater than or equal to (>=) 7 days
             prior to or after infusion)

        Exclusion Criteria:

          -  Untreated brain metastases. Subjects must have completed treatment for brain
             metastasis, and be neurologically stable off steroids, for at least 28 days prior to
             first dose of study drug

          -  History of listeriosis or vaccination with a listeria-based vaccine or prophylactic
             vaccine (eg, influenza, pneumococcal, diphtheria, tetanus, and pertussis [dTP/dTAP])
             within 28 days of study treatment

          -  Known allergy to both penicillin and trimethoprim/sulfamethoxazole. Participants who
             are allergic to only one of these antibiotics are allowed to enroll

          -  Concurrent treatment with anti-Tumor necrosis factor alpha (TNF alpha) therapies,
             systemic corticosteroids (prednisone dose greater than [>]10 mg per day or equivalent)
             or other immune suppressive drugs within the 2 weeks prior to Screening. Steroids that
             are topical, inhaled, nasal (spray) or ophthalmic solution are permitted

          -  Positive test result for human immunodeficiency virus (HIV) or acquired immune
             deficiency syndrome (AIDS)